Hot Stocks: Brokerages view on JB Pharma, BHEL, Hitachi Energy and HCL Tech
Brokerage companies like Bernstein upheld a Market Perform assessment for HCL Technologies, Nuvama endorsed a buy evaluation for BHEL, Jefferies suggested a buy stance on JB Pharma, and Goldman Sachs issued a buy rating for Hitachi Energy.
Brokerage firm maintained a Market Perform rating on , has a buy rating on , recommended a buy on and has a buy rating on .We have collated a list of recommendations from top brokerage firms from ETNow and other sources:
Bernstein on : HCL Technologies, , L&T Tech
Bernstein maintained a Market Perform rating on HCL Technologies but slashed the target price to Rs 1460 from Rs 1600 earlier.
It has a Market Perform rating on LTIMindTree but slashed the target price to Rs 4800 from Rs 5440 earlier.
L&T Technologies' target price was also cut to Rs 4070 from Rs 4470 earlier.
The brokerage firm is of the view that IT services is in 'mid to late cycle'. Cloud growth has been healthy, and Al-driven. However, IT services growth has remained subdued.
Nuvama on BHEL: Buy| Target Rs 400
Nuvama maintained a buy rating on BHEL but raised the target price to Rs 400 from Rs 265 earlier.
Higher provisioning hits profitability and the pipeline looks stronger. It is best placed to ride a thermal power wave over the next 12-24 months.
The brokerage firm revised FY25/26 EPS by (0.4)/7% given the execution of low OPM legacy orders till FY25 and pickup in new order execution from FY26.
Jefferies on JB Pharma: Buy| Target Rs 2060
Jefferies maintained a buy rating on but raised the target price to Rs 2060 from Rs 2000 earlier.
The company reported a small beat in 4Q, but growth drivers remain intact. India business is likely to witness high-teens growth in FY25. FY25 Ebitda margins guidance range increased by 1%.
Goldman Sachs on Hitachi Energy: Buy| Target Rs 8250
Goldman Sachs maintained a buy rating on Hitachi Energy with a target price of Rs 8250. Revenue outperformance offsets the margin miss.
The company reported double-digit EBITDA margin for the first time since Q2FY20. The order inflow and closing order book were up 11.5% and 6% YoY.
(Disclaimer: Recommendations, suggestions, views, and opinions given by experts are their own. These do not represent the views of the Economic Times)
It has a Market Perform rating on LTIMindTree but slashed the target price to Rs 4800 from Rs 5440 earlier.
L&T Technologies' target price was also cut to Rs 4070 from Rs 4470 earlier.
The brokerage firm is of the view that IT services is in 'mid to late cycle'. Cloud growth has been healthy, and Al-driven. However, IT services growth has remained subdued.
Nuvama on BHEL: Buy| Target Rs 400
Nuvama maintained a buy rating on BHEL but raised the target price to Rs 400 from Rs 265 earlier.
Higher provisioning hits profitability and the pipeline looks stronger. It is best placed to ride a thermal power wave over the next 12-24 months.
The brokerage firm revised FY25/26 EPS by (0.4)/7% given the execution of low OPM legacy orders till FY25 and pickup in new order execution from FY26.
Jefferies on JB Pharma: Buy| Target Rs 2060
Jefferies maintained a buy rating on but raised the target price to Rs 2060 from Rs 2000 earlier.
The company reported a small beat in 4Q, but growth drivers remain intact. India business is likely to witness high-teens growth in FY25. FY25 Ebitda margins guidance range increased by 1%.
Goldman Sachs on Hitachi Energy: Buy| Target Rs 8250
Goldman Sachs maintained a buy rating on Hitachi Energy with a target price of Rs 8250. Revenue outperformance offsets the margin miss.
The company reported double-digit EBITDA margin for the first time since Q2FY20. The order inflow and closing order book were up 11.5% and 6% YoY.
(Disclaimer: Recommendations, suggestions, views, and opinions given by experts are their own. These do not represent the views of the Economic Times)
Source: Stocks-Markets-Economic Times
